IRIDEX (NASDAQ:IRIX) Announces Earnings Results

IRIDEX (NASDAQ:IRIX) announced its quarterly earnings data on Tuesday. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same quarter in the prior year, the company earned ($0.11) EPS.

IRIDEX Stock Performance

Shares of NASDAQ IRIX opened at $1.77 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.86. The business has a 50-day moving average of $1.68 and a 200-day moving average of $2.03. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on IRIDEX in a research report on Saturday, November 9th. They set a “hold” rating on the stock.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.